Skip to main content
. 2015 Jun 11;3(7):646–649. doi: 10.1002/ccr3.297

Figure 3.

Figure 3

Treatment course: OEPA – vincristine 1.5 mg/m2/day №3, etoposide 125 mg/m2/day №5, prednisone 60 mg/m2/day №15, doxorubicine 40 mg/m2/day №2; COPDac – vincristine 1.5 mg/m2/day №2, prednisone 40 mg/m2/day №15, cyclophosphamide 500 mg/m2/day №2, dacarbasine 250 mg/m2/day №3; IEP – ifosphamide 2000 mg/m2/day №5, etoposide 125 mg/m2/day №5, prednisone 100 mg/m2/day №5, DHAP – dexamethasone 24 mg/m2/day №4, Ara-C 2000 mg/m2/twice a day №1, cisplatine 100 mg/m2/day №1; VGР – vinorelbine 25 mg/m2, gemcitabine 1000 mg/m2, prednisolone 100 mg/m2, BEAM – etoposide 200 mg/m2/day №4, melphalan125 mg/m2/day №1, Ara-C 200 mg/m2/twice a day №4, carmustine 100 mg/m2/day №1; BrVed – Brentuximab vedotine 1.8 mg/kg/day; BTFA, bendarmustine 240 mg/m2/day, treosulphane 42 mg/m2, fludarabine 150 mg/m2, antitymocyte globuline 50 mg/kg; PBSCT, peripheral blood stem cell transplantation (auto – autologous, haplo – haploidentical); 20 Gy, involved field irradiation; blue arrow – progression; green arrow – response.